EP3925614A3 — Melanocortin receptor ligands
Assigned to Ipsen Pharma SAS · Expires 2022-03-23 · 4y expired
What this patent protects
The present invention is directed to compounds according to the formula (R<sup>2</sup>R<sup>3</sup>)-A<sup>1</sup>-c (A<sup>2</sup>-A<sup>3</sup>-A<sup>4</sup>-A<sup>5</sup>-A<sup>6</sup&…
USPTO Abstract
The present invention is directed to compounds according to the formula (R<sup>2</sup>R<sup>3</sup>)-A<sup>1</sup>-c (A<sup>2</sup>-A<sup>3</sup>-A<sup>4</sup>-A<sup>5</sup>-A<sup>6</sup>-A<sup>7</sup>-A<sup>8</sup>-A<sup>9</sup>)-A<sup>10</sup>-R<sup>1</sup>, and pharmaceutically acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.